GBT
SNDX icon

Grove Bank & Trust’s Syndax Pharmaceuticals SNDX Stock Holding History

Grove Bank & Trust’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24
Closed -$348 – 693
2023
Q3 		$348 Buy
+24
New +$454 ﹤0.01% 733

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Grove Bank & Trust's SNDX Position: Q4 2023 in Review

Grove Bank & Trust sold out of Syndax Pharmaceuticals (SNDX) in Q4 2023, closing a stake of 24 shares — an estimated $348 sold.

Grove Bank & Trust first reported a position in SNDX in Q3 2023 and held it in 1 quarter. The position peaked at $348 in Q3 2023. 177 funds tracked by Wall St. Rank hold SNDX as of Q4 2023.

  • Grove Bank & Trust reported no remaining Syndax Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Grove Bank & Trust sold 24 Syndax Pharmaceuticals shares in Q4 2023, an estimated $348.
  • Grove Bank & Trust first reported a position in Syndax Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Grove Bank & Trust's Syndax Pharmaceuticals position peaked at $348 in Q3 2023.
  • 177 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.